Rossi R - Search Results

1

Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial.

Klingebiel T, Pertl U, Hess CF, Jürgens H, Koscielniak E, Pötter R, van Heek-Romanowski R, Rossi R, Schött C, Spaar HJ, Willnow U, Treuner J. Klingebiel T, et al. Among authors: rossi r. Med Pediatr Oncol. 1998 May;30(5):269-75. doi: 10.1002/(sici)1096-911x(199805)30:5<269::aid-mpo2>3.0.co;2-d. Med Pediatr Oncol. 1998. PMID: 9544222

2

Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System.

Stöhr W, Paulides M, Bielack S, Jürgens H, Treuner J, Rossi R, Langer T, Beck JD. Stöhr W, et al. Among authors: rossi r. Pediatr Blood Cancer. 2007 Apr;48(4):447-52. doi: 10.1002/pbc.20858. Pediatr Blood Cancer. 2007. PMID: 16628552

3

Ifosfamide-induced subclinical nephrotoxicity and its potentiation by cisplatinum.

Rossi R, Danzebrink S, Hillebrand D, Linnenbürger K, Ullrich K, Jürgens H. Rossi R, et al. Med Pediatr Oncol. 1994;22(1):27-32. doi: 10.1002/mpo.2950220106. Med Pediatr Oncol. 1994. PMID: 8232077

4

Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients.

Rossi R, Pleyer J, Schäfers P, Kuhn N, Kleta R, Deufel T, Jürgens H. Rossi R, et al. Med Pediatr Oncol. 1999 Mar;32(3):177-82. doi: 10.1002/(sici)1096-911x(199903)32:3<177::aid-mpo3>3.0.co;2-h. Med Pediatr Oncol. 1999. PMID: 10064184

5

Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system.

Stöhr W, Paulides M, Bielack S, Jürgens H, Koscielniak E, Rossi R, Langer T, Beck JD. Stöhr W, et al. Among authors: rossi r. Pediatr Blood Cancer. 2007 Feb;48(2):140-7. doi: 10.1002/pbc.20812. Pediatr Blood Cancer. 2007. PMID: 16724313

6

Concentrating capacity in ifosfamide-induced severe renal dysfunction.

Rossi R, Gödde A, Kleinebrand A, Rath B, Jürgens H. Rossi R, et al. Ren Fail. 1995 Sep;17(5):551-7. doi: 10.3109/08860229509037619. Ren Fail. 1995. PMID: 8570867

7

Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.

Rossi R, Gödde A, Kleinebrand A, Riepenhausen M, Boos J, Ritter J, Jürgens H. Rossi R, et al. J Clin Oncol. 1994 Jan;12(1):159-65. doi: 10.1200/JCO.1994.12.1.159. J Clin Oncol. 1994. PMID: 8270973

8

Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.

Silies H, Blaschke G, Hohenlöchter B, Rossi R, Jürgens H, Boos J. Silies H, et al. Among authors: rossi r. Int J Clin Pharmacol Ther. 1998 May;36(5):246-52. Int J Clin Pharmacol Ther. 1998. PMID: 9629987

9

Subclinical impairment of renal function after radiotherapy for Hodgkin's disease in children.

Pötter R, Roes F, Schellong G, Bartenstein P, Brämswig JH, von Lengerke HJ, Rath B, Mohring R, Rossi R. Pötter R, et al. Among authors: rossi r. Recent Results Cancer Res. 1993;130:259-67. doi: 10.1007/978-3-642-84892-6_23. Recent Results Cancer Res. 1993. PMID: 8362095 Clinical Trial. No abstract available.

10

Growth impairment after ifosfamide-induced nephrotoxicity in children.

Stöhr W, Patzer L, Paulides M, Kremers A, Beck JD, Langer T, Rossi R. Stöhr W, et al. Among authors: rossi r. Pediatr Blood Cancer. 2007 May;48(5):571-6. doi: 10.1002/pbc.20920. Pediatr Blood Cancer. 2007. PMID: 16755549

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,075 results

Search Page

Filters